Answers are grounded in this paper and cite their sources.
-acetylgalactosamine (GalNAc) ligand. This ligand enables efficient uptake of the nucleic acid by the asialoglycoprotein receptor (ASGP-R) on hepatocytes. Synthetic multivalent ligands for ASGP-R were among the first 'cluster glycosides' developed at the birth of multivalent glycoscience around 40 years ago. In this review we trace the history of 'GalNAc targeting' from early academic studies to current pharmaceuticals and consider what other opportunities could follow the success of this delivery technology.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: